吡咯生物碱相关肝窦阻塞综合征发病机制的研究进展  

Research advances in the pathogenesis of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome

作　　者：刘文成 李琰 常冰[1] LIU Wencheng;LI Yan;CHANG Bing(Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China)

机构地区：[1]中国医科大学附属第一医院消化内科,沈阳110001

出　　处：《临床肝胆病杂志》2021年第4期962-964,共3页Journal of Clinical Hepatology

基　　金：国家自然科学基金(81400618);沈阳市科技计划项目(20-205-4-094)。

摘　　要：吡咯生物碱诱导的肝窦阻塞综合征主要原因为摄入了含吡咯生物碱的中草药或食品。从药物因素、宿主因素、影响因素三个方面,回顾了近年来吡咯生物碱及其代谢产物参与疾病发生发展机制的研究进展。认为吡咯生物碱相关肝窦阻塞综合征的发病机制复杂、影响因素较多,部分患者预后较差,且发病机制尚未十分明确,有必要进一步深入研究。Pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome(PA-HSOS)is a type of hepatic sinusoidal obstruction syndrome mainly caused by the intake of Chinese herbal medicine or food containing pyrrolizidine alkaloids.This article reviews the recent research advances in the mechanism of action of pyrrolizidine alkaloids and their metabolites in disease development and progression from the aspects of drug factors,host factors,and influencing factors.It is pointed out that PA-HSOS has complex pathogenesis and various influencing factors,and some patients tend to have a poor prognosis;its pathogenesis remains unclear and needs further in-depth studies.

关 键 词：肝静脉闭塞性疾病 病理过程 吡咯生物碱 

分 类 号：R575[医药卫生—消化系统]